Study gives pointers on why patients are reluctant to disclose sexual orientation

Study gives pointers on why patients are reluctant to disclose sexual orientation

February 1 2018 A study has flagged up patients’ concerns about the need to disclose their...

NHS England extends lease practice incentive scheme to March 31

NHS England extends lease practice incentive scheme to March 31

January 23 2018 A scheme to support any GP practice that is a tenant in an NHS Property Services...

£3.9m boost for GP services in Northern Ireland

£3.9m boost for GP services in Northern Ireland

December 21 2017 General practices in Northern Ireland are to benefit from £3.9 million in...

  • Study gives pointers on why patients are reluctant to disclose sexual orientation

    Study gives pointers on why patients are reluctant to disclose sexual orientation

    Thursday, 01 February 2018 11:35
  • NHS England extends lease practice incentive scheme to March 31

    NHS England extends lease practice incentive scheme to March 31

    Tuesday, 23 January 2018 12:19
  • £3.9m boost for GP services in Northern Ireland

    £3.9m boost for GP services in Northern Ireland

    Thursday, 21 December 2017 10:35

a man taking medication imageFebruary 2 2018

Details of the review into prescribed medicines that may cause dependence or withdrawal have been set out.


Public Health Minister Steve Brine has commissioned Public Health England to review the evidence and report back in early 2019. It has been asked to look at:

  • prevalence and prescribing patterns;
  • the nature and likely causes of dependence or discontinuation syndrome among some people who take these medicines;
  • effective prevention and treatment of dependence and discontinuation syndrome for each drug category.

Drug classes specifically targeted will be benzodiazepines, Z-drugs, GABA-ergic medicines, opioid pain medications, antidepressants, as well as those that are prescribed to treat anxiety, insomnia, chronic non-cancer pain and depression. The review will look at the use of the medicines by adults, and community prescribing.

Not included in the review’s remit are:

  • cancer and terminal pain;
  • over-the-counter medicines;
  • prescribing in hospitals and prisons;
  • other medicines, such as anti-psychotics, stimulants, ‘smart drugs’, or anti-obesity drugs.

PHE will use a number of methods to gather evidence, including “analysing all prescription and some GP patient data to understand prevalence and detail of prescribing patterns, patients and conditions.”

Link:
PHE announcement      

Management News

February 21 2018 Public Health Wales has published further information about the tendering process for GP software which has seen EMIS Health not able to continue as a supplier.
February 20 2018 New British Thoracic Society guidelines on pleural mesothelioma include some key recommendations for primary care. The BTS guideline give recommendations and good practice points...